ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Q2 FY27 revenue ₹206 Cr (+3.2% YoY), EBITDA ₹45 Cr (-37.5%), margin 22%. LATAM regulatory shock, Ambernath ramp-up costs and raw material inflation hit margins; FY27 margin guidance cut to 23–25%.
Supriya Lifescience's Q2 FY27 revenue rose 3.2%, but EBITDA and PAT fell sharply. Ambernath ramp-up costs and LATAM regulatory shifts hurt margins.
Supriya Lifescience Ltd reported revenue from operations of ₹206.3 Cr (+3.3% YoY) and net profit of ₹29.2 Cr (-42.1% YoY) for Q2 FY27.
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Supriya Lifescience will hold a board meeting on 6 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after results are declared.
Supriya Lifescience disclosed a pending case was admitted by the Supreme Court. An interim order precludes coercive action against directors while the matter is sub judice.
Supriya Lifescience disclosed a CRISIL ESG rating of 65 in the Strong category. No financial or operational event accompanies the disclosure.
Supriya Lifescience has filed a petition with the Supreme Court of India regarding ongoing judicial proceedings. The matter is currently sub judice and pending consideration.
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience Ltd has issued the notice for its 18th Annual General Meeting scheduled for September 24, 2026, alongside the Annual Report for FY 2025-26.
Supriya Lifescience Limited has fixed September 4, 2026, as the record date for its final dividend of Re. 1.00 per share. The dividend awaits AGM approval.
Supriya Lifescience Ltd. shareholders approved the re-appointment of Mr. Balasaheb Sawant as Whole Time Director via postal ballot, as per the voting results.
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.
Supriya Lifescience announced financial highlights for Q1 FY27, reporting revenue of Rs. 189.75 crore and profit after tax of Rs. 24.04 crore for the quarter.
Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, up 31% YoY, despite EBITDA and PAT compression. The company is pivoting towards new markets and backward integration to stabilize margins.
Supriya Lifescience Ltd reported revenue from operations of ₹189.7 Cr (+30.7% YoY) and net profit of ₹24 Cr (-31.0% YoY) for Q1 FY27.
Supriya Lifescience Ltd scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Supriya Lifescience Ltd issued a Postal Ballot Notice to shareholders seeking approval for the re-appointment of Mr. Balasaheb Sawant as a Whole Time Director.
Supriya Lifescience Ltd has submitted its quarterly shareholding pattern under SEBI regulations. This filing discloses the stake distribution among promoters and the general public.
Supriya Lifescience disclosed legal proceedings against its GM under NDPS Act. Company states no material financial or operational impact is expected.
Supriya Lifescience achieved record Q4 revenue of ₹277cr, bringing FY26 revenue to ₹828cr. Management maintained its guidance of 20% annual growth and 33-35% EBITDA margins.
Supriya Lifescience Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. The auditor reported no deviations or non-compliances, confirming regulatory adherence.
Supriya Lifescience delivered strong FY26 results with Q4 revenue surging 50% YoY, driven by the anesthetic segment and European market dominance.
Supriya Lifescience reported FY26 revenue of ₹827.87 Crore, up 18.9% YoY. Strong Q4 performance and capacity expansion signal robust growth across key therapeutic segments.
Supriya Lifescience recommended a final dividend of ₹1 per equity share for the 2025-2026 financial year. This board recommendation reflects the company's commitment to returning capital to shareholders.
Supriya Lifescience delivered strong performance in Q4FY26 with 50% YoY revenue growth, driven by expansion in Europe and new product launches in Cardiovascular and ADHD segments.